CN111588815A - 一种祛痘中药组合物及其应用与含有该组合物的祛痘平衡精华 - Google Patents
一种祛痘中药组合物及其应用与含有该组合物的祛痘平衡精华 Download PDFInfo
- Publication number
- CN111588815A CN111588815A CN202010479732.9A CN202010479732A CN111588815A CN 111588815 A CN111588815 A CN 111588815A CN 202010479732 A CN202010479732 A CN 202010479732A CN 111588815 A CN111588815 A CN 111588815A
- Authority
- CN
- China
- Prior art keywords
- acne
- parts
- extract
- chinese medicine
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010000496 acne Diseases 0.000 title claims abstract description 117
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 115
- 239000003814 drug Substances 0.000 title claims abstract description 51
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 239000000284 extract Substances 0.000 claims abstract description 63
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 16
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 claims abstract description 16
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 claims abstract description 16
- 229930014456 matrine Natural products 0.000 claims abstract description 16
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 11
- 229940067866 dandelion extract Drugs 0.000 claims abstract description 11
- 235000020691 dandelion extract Nutrition 0.000 claims abstract description 11
- 239000001845 taraxacum officinale leaf extract Substances 0.000 claims abstract description 11
- 241000972672 Phellodendron Species 0.000 claims abstract description 9
- 239000010404 Scutellaria baicalensis extract Substances 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims abstract description 9
- 230000002195 synergetic effect Effects 0.000 claims abstract description 9
- 241001671203 Stemona japonica Species 0.000 claims abstract description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 30
- 238000003756 stirring Methods 0.000 claims description 28
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 20
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 20
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
- 239000000463 material Substances 0.000 claims description 19
- 238000006243 chemical reaction Methods 0.000 claims description 13
- 239000004475 Arginine Substances 0.000 claims description 12
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 12
- 238000001816 cooling Methods 0.000 claims description 12
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 11
- 229960001915 hexamidine Drugs 0.000 claims description 11
- OQLKNTOKMBVBKV-UHFFFAOYSA-N hexamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCCOC1=CC=C(C(N)=N)C=C1 OQLKNTOKMBVBKV-UHFFFAOYSA-N 0.000 claims description 11
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 11
- 229960003966 nicotinamide Drugs 0.000 claims description 11
- 235000005152 nicotinamide Nutrition 0.000 claims description 11
- 239000011570 nicotinamide Substances 0.000 claims description 11
- 125000001453 quaternary ammonium group Chemical class 0.000 claims description 11
- 239000011670 zinc gluconate Substances 0.000 claims description 11
- 229960000306 zinc gluconate Drugs 0.000 claims description 11
- 235000011478 zinc gluconate Nutrition 0.000 claims description 11
- MXOAEAUPQDYUQM-QMMMGPOBSA-N (S)-chlorphenesin Chemical compound OC[C@H](O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-QMMMGPOBSA-N 0.000 claims description 10
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 10
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 10
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 10
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 10
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 10
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 10
- 229960003993 chlorphenesin Drugs 0.000 claims description 10
- 229920006037 cross link polymer Polymers 0.000 claims description 10
- 150000002148 esters Chemical class 0.000 claims description 10
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 10
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 10
- 229960005323 phenoxyethanol Drugs 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 230000008439 repair process Effects 0.000 claims description 10
- 229960004889 salicylic acid Drugs 0.000 claims description 10
- 239000000230 xanthan gum Substances 0.000 claims description 10
- 229920001285 xanthan gum Polymers 0.000 claims description 10
- 235000010493 xanthan gum Nutrition 0.000 claims description 10
- 229940082509 xanthan gum Drugs 0.000 claims description 10
- 235000014104 aloe vera supplement Nutrition 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 claims description 8
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims description 8
- 230000000844 anti-bacterial effect Effects 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- -1 hydroxypropyl Chemical group 0.000 claims description 5
- 239000008367 deionised water Substances 0.000 claims description 4
- 229910021641 deionized water Inorganic materials 0.000 claims description 4
- 235000015097 nutrients Nutrition 0.000 claims description 4
- 229960001860 salicylate Drugs 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 claims description 4
- 230000008719 thickening Effects 0.000 claims description 4
- 239000002562 thickening agent Substances 0.000 claims description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- 241000207929 Scutellaria Species 0.000 claims description 2
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 2
- 239000000419 plant extract Substances 0.000 claims description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims description 2
- 239000000686 essence Substances 0.000 abstract description 39
- 230000000694 effects Effects 0.000 abstract description 29
- 206010061218 Inflammation Diseases 0.000 abstract description 9
- 229940088710 antibiotic agent Drugs 0.000 abstract description 9
- 230000006870 function Effects 0.000 abstract description 7
- 230000004054 inflammatory process Effects 0.000 abstract description 7
- 230000003467 diminishing effect Effects 0.000 abstract description 6
- 230000001954 sterilising effect Effects 0.000 abstract description 6
- 201000004624 Dermatitis Diseases 0.000 abstract description 5
- 241000196324 Embryophyta Species 0.000 abstract description 5
- 239000005556 hormone Substances 0.000 abstract description 5
- 229940088597 hormone Drugs 0.000 abstract description 5
- 230000036039 immunity Effects 0.000 abstract description 5
- 230000003266 anti-allergic effect Effects 0.000 abstract description 4
- 239000006071 cream Substances 0.000 abstract description 4
- 206010059866 Drug resistance Diseases 0.000 abstract description 3
- 230000000172 allergic effect Effects 0.000 abstract description 3
- 208000010668 atopic eczema Diseases 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 230000007774 longterm Effects 0.000 abstract description 3
- 230000008929 regeneration Effects 0.000 abstract description 3
- 238000011069 regeneration method Methods 0.000 abstract description 3
- 150000003839 salts Chemical class 0.000 abstract description 3
- 230000000638 stimulation Effects 0.000 abstract description 3
- 230000003197 catalytic effect Effects 0.000 abstract description 2
- 239000002085 irritant Substances 0.000 abstract description 2
- 231100000021 irritant Toxicity 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 53
- 238000012360 testing method Methods 0.000 description 41
- 239000000047 product Substances 0.000 description 10
- 230000007794 irritation Effects 0.000 description 9
- 210000002374 sebum Anatomy 0.000 description 9
- 238000005303 weighing Methods 0.000 description 9
- 210000001061 forehead Anatomy 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 208000026935 allergic disease Diseases 0.000 description 5
- 230000007815 allergy Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 230000036407 pain Effects 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 241000186427 Cutibacterium acnes Species 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 210000003780 hair follicle Anatomy 0.000 description 4
- 238000000265 homogenisation Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000003405 preventing effect Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 229940055019 propionibacterium acne Drugs 0.000 description 4
- 206010040882 skin lesion Diseases 0.000 description 4
- 231100000444 skin lesion Toxicity 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 208000020154 Acnes Diseases 0.000 description 3
- 229920000832 Cutin Polymers 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000003385 bacteriostatic effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 239000004519 grease Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 239000003999 initiator Substances 0.000 description 3
- 239000004816 latex Substances 0.000 description 3
- 229920000126 latex Polymers 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 231100000241 scar Toxicity 0.000 description 3
- 239000000344 soap Substances 0.000 description 3
- BGEBZHIAGXMEMV-UHFFFAOYSA-N 5-methoxypsoralen Chemical compound O1C(=O)C=CC2=C1C=C1OC=CC1=C2OC BGEBZHIAGXMEMV-UHFFFAOYSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 241000212948 Cnidium Species 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010034972 Photosensitivity reaction Diseases 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000003255 anti-acne Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000001732 sebaceous gland Anatomy 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- DBMJZOMNXBSRED-UHFFFAOYSA-N Bergamottin Natural products O1C(=O)C=CC2=C1C=C1OC=CC1=C2OCC=C(C)CCC=C(C)C DBMJZOMNXBSRED-UHFFFAOYSA-N 0.000 description 1
- GIJHDGJRTUSBJR-UHFFFAOYSA-N Bergaptol Natural products O1C(=O)C=CC2=C1C=C1OC=CC1=C2O GIJHDGJRTUSBJR-UHFFFAOYSA-N 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 241000026010 Dendrobium candidum Species 0.000 description 1
- 241001076416 Dendrobium tosaense Species 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- RNKZFOIQKCQOAQ-UHFFFAOYSA-N Isopimpinellin Natural products COC1CC(=O)Oc2c(OC)c3occc3cc12 RNKZFOIQKCQOAQ-UHFFFAOYSA-N 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 241000192132 Leuconostoc Species 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- HPUXDMUGCAWDFW-UHFFFAOYSA-N Osthole Natural products COc1ccc2CCC(=O)Oc2c1C=CC(=O)C HPUXDMUGCAWDFW-UHFFFAOYSA-N 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000972673 Phellodendron amurense Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 244000296102 Selinum monnieri Species 0.000 description 1
- 235000019084 Selinum monnieri Nutrition 0.000 description 1
- 241001671204 Stemona Species 0.000 description 1
- 241000417534 Stemona sessilifolia Species 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 241000223238 Trichophyton Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- YXCORZFYRFZUOV-UHFFFAOYSA-N Xanthotoxol Natural products COc1c2OC(O)C=Cc2cc3ccoc13 YXCORZFYRFZUOV-UHFFFAOYSA-N 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960002045 bergapten Drugs 0.000 description 1
- KGZDKFWCIPZMRK-UHFFFAOYSA-N bergapten Natural products COC1C2=C(Cc3ccoc13)C=CC(=O)O2 KGZDKFWCIPZMRK-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001877 deodorizing effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 231100000013 eye irritation Toxicity 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 230000001329 hyperkeratotic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- DFMAXQKDIGCMTL-UHFFFAOYSA-N isopimpinellin Chemical compound O1C(=O)C=CC2=C1C(OC)=C1OC=CC1=C2OC DFMAXQKDIGCMTL-UHFFFAOYSA-N 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- MBRLOUHOWLUMFF-UHFFFAOYSA-N osthole Chemical compound C1=CC(=O)OC2=C(CC=C(C)C)C(OC)=CC=C21 MBRLOUHOWLUMFF-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 208000007578 phototoxic dermatitis Diseases 0.000 description 1
- 231100000018 phototoxicity Toxicity 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- JWVYQQGERKEAHW-UHFFFAOYSA-N xanthotoxol Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2O JWVYQQGERKEAHW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/234—Cnidium (snowparsley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/904—Stemonaceae (Stemona family), e.g. croomia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/442—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof substituted by amido group(s)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
- A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/738—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/008—Preparations for oily skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/30—Characterized by the absence of a particular group of ingredients
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Botany (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明提供一种祛痘中药组合物，所述组合物包括：苦参碱20‑40份、蛇床子提取物24‑30份、黄芩提取物20‑28份、忍冬花提取物17‑24份、蒲公英提取物12‑20份、黄柏提取物11‑17份和蔓生百部提取物9‑14份。本发明采用性能优异的苦参碱为核心原料，复配多种具有消炎杀菌和抗敏修复功能的中药精华和植物精华，外加高效、安全、无刺激性盐类增效祛痘成分做引导剂，独创的催化动力学技术，使本来起效很慢的中药和植物精华迅速起效，从而实现快速除痘，抗敏修复。最大限度采用天然成分，除痘不伤肤，无刺激，不过敏，不含抗生素和激素，长期使用，肌肤不会产生耐药性。同时提升肌肤免疫力，减少皮肤过敏和粉刺再生。
Description
技术领域
本发明属于中药组合物领域，具体涉及一种祛痘中药组合物及其应用与含有该组合物的祛痘平衡精华。
背景技术
青春痘，医学名称为：寻常性痤疮；别称：粉刺、暗疮、酒刺、面苞，是一种毛囊皮脂腺极其常见的慢性炎症性皮肤病。
青春痘的形成通常是多种因素综合作用的结果。主要与遗传因素、内分泌因素和面部清洁卫生、饮食习惯、长期精神紧张、情绪波动、学习及生活环境等因素有关，这些因素很容易导致皮脂代谢紊乱，皮肤油脂分泌过于旺盛，毛囊、皮脂腺过度角化，使毛囊口变狭窄、闭塞，使得微生物大量滋生聚集，随着油脂、角质细胞异常分化越堆越多，从而引发炎症，肌肤就长出了粉刺。如果没有妥善地处理，这些粉刺就会继续被细菌感染发炎，最后一路从丘疹，到结节，到囊肿，留下疤痕和痘印。
痤疮是一种自限性疾病，不作任何治疗迟早也会痊愈。但是通过治疗手段，可加快这一时程，消减患者的痛苦，降低严重程度，减少瘢痕形成，促进瘢痕修复。痤疮的发病非常普遍，患者在不是特别严重的情况下，一般不会去医院接受治疗。因此通过使用具有抗炎祛痘修复功效的化妆品达到舒缓及治愈目的，是很受消费者欢迎的一种方式，这类化妆品也具有比较大的应用前景。
时至今日，祛痘化妆品技术的发展基本上经历了三个阶段：
第一阶段：2000年以前，以“抗生素+激素”为主体的抗生素祛痘技术；以复合抗生素为主要祛痘活性成分，以激素降低刺激，虽见效快、有效率高、成本低，但刺激性大、过敏率高，会生成抗体、产生耐药性，使肌肤免疫功能下降。
第二阶段：2001年-2006年，以“中草药精华+抗生素”为主体的生物祛痘技术；为解决祛痘产品刺激和过敏的问题，以具有杀菌消炎功能的复合中药提取液为主活性成分，以抗生素为引发剂和催化剂，虽相对安全，但依然含有抗生素、有风险。
2005年5月23日在奥兰多召开的美国微生物协会的年会上：瑞典斯德哥尔摩Karolinska研究所的Carl Eeik Nord博士报道了他的研究成果：“对抗生素耐药的痤疮丙酸杆菌的日益增多可能意味着应限制抗生素治疗痤疮，并试验其他疗法。”
我国“化妆品卫生管理规范”(2007版)再一次将抗生素和激素列为化妆品禁止使用的原料，并且不断加大对这类规范产品的打击力度。
第三阶段：2006年至今，以“天然原料+引发剂”为主体的无抗生素祛痘技术。以具有杀菌消炎功效的复合中药提取物或植物精华液为主活性成分，以蛋白酶等引发剂为辅助成分催化反应，见效快，有效率高，成本低，刺激小，安全无风险，便于应用。
例如，中国专利申请CN201811616891.8提供一种包括金叉石斛提取物、铁皮石斛提取物、苦参碱、明串球菌/萝卜根发酵产物滤液、透皮EGF等成分的祛痘修复精华。但要针对粉刺皮肤的生理病理特点作安全有效的全程护理，还需要有进一步优化、丰富的配方。
发明内容
有鉴于此，为了克服现有技术的不足，本发明提供一种祛痘中药组合物。
本发明提供的祛痘中药组合物，所述组合物包括：苦参碱20-40份、蛇床子提取物24-30份、黄芩提取物20-28份、忍冬花提取物17-24份、蒲公英提取物12-20份、黄柏提取物11-17份和蔓生百部提取物9-14份。
优选地，所述组合物由如下重量份的组分组成：苦参碱30份、蛇床子提取物28份、黄芩提取物24份、忍冬花提取物20份、蒲公英提取物16份、黄柏提取物14份和蔓生百部提取物11份。
本发明还提供上述祛痘中药组合物或优选祛痘中药组合物在制备祛痘护肤品中的应用。
本发明还提供一种祛痘平衡精华，所述祛痘平衡精华包括如下重量百分比计的原料：
上述的祛痘中药组合物或优选的祛痘中药组合物6-34％；
增效祛痘成分：葡糖酸锌0.1-0.7％、季铵盐-73 0.001-0.004％、水杨酸羟丙基倍他环糊精包合物5.6-8％和己脒定二(羟乙基磺酸)盐0.08-0.10％；
辅助营养修复成分：精氨酸0.08-0.19％、烟酰胺2-10％和库拉索芦荟提取物3-7％；
增稠稳定剂：丙烯酸(酯)类/C10-30烷醇丙烯酸酯交联聚合物0.01-3％、黄原胶0.3％-1％和羟乙基纤维素0.2-0.4％；
抗菌成分：苯氧乙醇0.2％-1％、氯苯甘醚0.07-0.2％、1,2戊二醇0.03-0.1％和对羟基苯乙酮0.01-0.06％；
甘油3-7％、丙二醇2～l0％和乙醇2-5％；
其余重量为去离子水。
优选地，所述祛痘平衡精华包括如下重量百分比计的原料：
上述祛痘中药组合物或优选的祛痘中药组合物25％；
增效祛痘成分：葡糖酸锌0.3％、季铵盐-730.002％、水杨酸羟丙基倍他环糊精包合物7％和己脒定二(羟乙基磺酸)盐0.09％；
辅助营养修复成分：精氨酸0.15％、烟酰胺2.4％和库拉索芦荟提取物7％；
增稠稳定剂：丙烯酸(酯)类/C10-30烷醇丙烯酸酯交联聚合物2％、黄原胶0.6％和羟乙基纤维素0.3％；
抗菌剂：苯氧乙醇0.2％、氯苯甘醚0.1％、1,2戊二醇0.05％和对羟基苯乙酮0.03％、甘油3.5％、丙二醇0.2％、乙醇2％；
其余重量为去离子水。
本发明还提供上述祛痘平衡精华的制备方法，所述制备方法包括步骤：
(1)将所述重量百分比的甘油、丁二醇、烟酰胺、丙烯酸(酯)类/C10-30烷醇丙烯酸酯交联聚合物混合均匀，得到A相料；
(2)将所述重量百分比的水、A相料、丙二醇、黄原胶、羟乙基纤维素，对羟基苯乙酮、1,2戊二醇依次加入水锅中，加热到80-85℃，搅拌至溶解均匀，保温20min；
(3)开冷却循环水、搅拌降温，得温度降至45-50℃时，将所述重量百分比的精氨酸、己脒定二(羟乙基磺酸)盐、水杨酸羟丙基倍他环糊精包合物、苯氧乙醇、氯苯甘醚依次加入反应罐中，均质1分钟，搅拌溶解完全；
(4)继续搅拌冷却至低于37℃，将所述重量百分比的季铵盐-73、植物提取物、葡糖酸锌乙醇，依次加入反应罐中，均质2-3分钟，搅拌溶解完全，结束。
本发明祛痘中药组合物中：
苦参碱能够平衡肌肤的油脂分泌，疏通并收敛毛孔，清除皮肤内毒素杂质；对痤疮丙酸杆菌有突出的抑菌效率，具有抗菌消炎的功效，能高效抑制青春痘的生长；对胶原蛋白生产具有促进作用，对成纤维细胞的增殖也有促进作用，可用作皮肤抗衰老；同时具有保湿的功效。其丰富的本草营养能促进受损血管神经细胞的生长和修复，恢复皮下毛细管细胞活力，肌肤重现紧致细滑，起到美容护肤作用。
蛇床子提取物能杀菌、止痒，预防过敏症状；蛇床子提取物中四种物质：蛇床子素、佛手柑内酯、异虎耳草素和花椒毒酚；前三者对发癣菌有很强的抑制作用，后一种有明显的抗霉菌作用。所以自古以来，蛇床子都被视为治疗皮肤病和瘙痒症的核心药物。
黄芩提取物能抑制和干扰弹性蛋白酶分泌，消除自由基，从而增加皮肤新陈代谢、增加皮肤弹性和抗皱性，抗衰老；促进脑酰胺代谢而改善皮脂，使皮肤柔润；能抑制皮炎、增强皮肤的抵抗力；能中和释放的组织胺，具有防止过敏的能力。
蒲公英提取物有很好的杀菌和抑菌作用，结合其抗炎性、对雄激素分泌的抑制，可用于预防皮肤炎症如粉刺；同时能促进芽细胞等的生长，消除自由基，具有抗氧化，减缓衰老作用；也能用做抗敏剂。
忍冬花提取物中活性成分绿原酸,具有强烈的抗菌、减脂美肤和防止皮肤老化的作用。对皮肤的渗透力强，可达到皮肤深处，忍冬花水提物经过透明质酸酶体外抑制实验检测出其对透明质酸的抑制率达到69.54％，具有良好的抗敏性。并且忍冬花提取物在红细胞溶血试验中的溶血率小于20％，说明它对人体皮肤的刺激性比较小，也可以减少化学试剂对皮肤的刺激性。并可消除自由基、抑制和消除皮肤色斑。
蔓生百部提取物有超氧化物歧化酶(SOD)样作用，对超氧自由基有较好的消除作用，是很好的自由基捕获剂；同时有极强的抗菌性。
本发明祛痘平衡精华中包含如下增效祛痘成分：
羟丙基环糊精包合水杨酸：固体包合物可以达到完全水溶，克服了水杨酸稳定性差，刺激性大的缺陷。很好的解决了水杨酸应用中的缺陷而保持了其优点，包合率高，水溶液稳定性好，易于保存、运输及使用，用于祛痘、清理毛孔、美白、促进角质更新和杀灭真菌。
葡糖酸锌：矿物质类能量补充剂，刺激细胞能量和新陈代谢的介质，有效激活皮肤细胞活性，为细胞新陈代谢提供可渗透性的微量元素；活性添加剂的增效剂，促进配方中其它活性成分的吸收及有效利用；与细胞亲和性较佳的有机盐，能有效渗透进肌肤，促进肌肤的新陈代谢，使肌肤得以修复，清除自由基。同时，锌离子帮皮肤平衡出油，减少因油脂分泌旺盛导致毛孔“堵”和冒痘的风险；维持上皮组织和粘膜完整，防御细菌感染、促进伤口愈合，改善已成型的痘痘。
季铵盐-73具有超高活性的抑菌能力，可以在低浓度情况下抑制痤疮杆菌的活性，而且该原料在进行皮肤测试，眼刺激性测试，光敏性，光毒性，以及基因突变型等测试均为阴性；还具有抑制黑色素生成作用，能够在一定程度上抑制痤疮创面愈合后的黑色素沉积，达到祛痘的作用。
己脒定二(羟乙基磺酸)盐具有高效杀菌性、无刺激性和高安全性。
本发明祛痘平衡精华中还包含如下辅助营养修复成分：
精氨酸：在皮肤和结缔组织中，精氨酸浓度较高时，这有助于损伤组织的愈合和修复。
烟酰胺：皮肤抗老化成份，最重要的功效是减轻和预防皮肤在早期衰老过程中产生的肤色黯淡、发黄、菜色。也可修复受损的角质层脂质屏障，提高皮肤抵抗力，并有深层锁水功效。
库拉索芦荟提取物：首先，具有湿润、美容、美白防晒、修复皮肤的作用；其次，具有抗衰老、解毒的作用；再者，具有免疫、抗肿瘤以及杀菌抗炎的作用；最后，具有镇痛，镇定，防臭作用。
本发明的有益效果在于：
1.协同增效的中药组合物：本发明采用性能优异的苦参碱为核心原料，复配多种具有消炎杀菌和抗敏修复功能的中药精华和植物精华，君药臣药之间协同增效，控油祛痘效果远大于各组分效果之和。
2.高效快速祛痘：本发明采用性能优异的控油祛痘中药组合物，外加高效、安全、无刺激性盐类辅助祛痘成分做引导剂，独创的催化动力学技术，使本来起效很慢的中药和植物精华迅速起效，从而实现快速除痘，抗敏修复。
3.高安全性：本发明最大限度采用天然成分，除痘不伤肤，无刺激，不过敏，不含抗生素和激素，长期使用，肌肤不会产生耐药性。
4.组织修复并提升肌肤免疫力：修复肌肤上皮层的受损组织，祛痘不留疤痕；同时提升肌肤免疫力，减少皮肤过敏和粉刺再生。
5.角质处理和深层锁水：去除外层积聚过厚的死皮，畅通毛囊，补充水分，还原面部均匀剔透肤色；并维持肌肤水分生理平衡，为表层皮肤提供更有利的生态环境。
6.实现安全、有效的全程护理：针对皮肤的生理病理特点，从粉刺皮肤油脂控制和角质代谢的源头着手，平衡控油、角质处理、杀菌消炎、修复再生和提升免疫力等对粉刺皮肤实现全程综合护理。
具体实施方式：
以下实施例是对本发明的解释而本发明并不局限于以下实施例。
实施例1：本发明的祛痘中药组合物
称取苦参碱30份、蛇床子提取物28份、黄芩提取物24份、忍冬花提取物20份、蒲公英提取物16份、黄柏提取物14份、蔓生百部提取物11份，混合均匀，形成祛痘中药组合物。
实施例2：本发明的祛痘中药组合物
称取苦参碱20份、蛇床子提取物24份、黄芩提取物20份、忍冬花提取物17份、蒲公英提取物12份、黄柏提取物11份、蔓生百部提取物9份，混合均匀，形成祛痘中药组合物。
实施例3：本发明的祛痘中药组合物
称取苦参碱40份、蛇床子提取物30份、黄芩提取物28份、忍冬花提取物24份、蒲公英提取物20份、黄柏提取物17份、蔓生百部提取物14份，混合均匀，形成祛痘中药组合物。
实施例4：本发明的祛痘中药组合物
称取苦参碱35份、蛇床子提取物25份、黄芩提取物26份、忍冬花提取物23份、蒲公英提取物16份、黄柏提取物15份、蔓生百部提取物11份，混合均匀，形成祛痘中药组合物。
对比例1：
称取蛇床子提取物28份、黄芩提取物24份、忍冬花提取物20份、蒲公英提取物16份、黄柏提取物14份、蔓生百部提取物11份，混合均匀，形成祛痘中药组合物。
对比例2：
纯的苦参碱粉末。
实施例5：本发明祛痘平衡精华及其制备方法：
实施例1的祛痘中药组合物250g；
按照下述步骤制备本发明祛痘平衡精华：
(1)称取35g甘油、24g烟酰胺、20g丙烯酸(酯)类/C10-30烷醇丙烯酸酯交联聚合物混合均匀，得到A相料；
(2)将513g水、A相料、20g丙二醇、6g黄原胶、3g羟乙基纤维素，0.3g对羟基苯乙酮、0.5g 1,2戊二醇依次加入水锅中，加热到80-85℃，搅拌至溶解均匀，保温20min；
(3)开冷却循环水、搅拌降温，得温度降至45-50℃时，将1.5g精氨酸、0.9g己脒定二(羟乙基磺酸)盐、70g水杨酸羟丙基倍他环糊精包合物、2g苯氧乙醇、1g氯苯甘醚依次加入反应罐中，均质1分钟，搅拌溶解完全；
(4)继续搅拌冷却至低于37℃，将0.02g季铵盐-73、实施例1的250g祛痘中药组合物、70g库拉索芦荟提取物、3g葡糖酸锌和20g无水乙醇,依次加入反应罐中，均质2-3分钟，搅拌溶解完全，结束。
实施例6：本发明祛痘平衡精华的制备方法：
实施例2的祛痘中药组合物340g；
按照下述步骤制备本发明祛痘平衡精华：
(1)称取70g甘油、100g烟酰胺、30g丙烯酸(酯)类/C10-30烷醇丙烯酸酯交联聚合物混合均匀，得到A相料；
(2)将123g水、A相料、100g丙二醇、10g黄原胶、4g羟乙基纤维素，0.6g对羟基苯乙酮、1g 1,2戊二醇依次加入水锅中，加热到80-85℃，搅拌至溶解均匀，保温20min；
(3)开冷却循环水、搅拌降温，得温度降至45-50℃时，将1.9g精氨酸、1.0g己脒定二(羟乙基磺酸)盐、80g水杨酸羟丙基倍他环糊精包合物、10g苯氧乙醇、2g氯苯甘醚依次加入反应罐中，均质1分钟，搅拌溶解完全；
(4)继续搅拌冷却至低于37℃，将0.04g季铵盐-73、实施例2的340g祛痘中药组合物、70g库拉索芦荟提取物、7g葡糖酸锌和50g无水乙醇,依次加入反应罐中，均质2-3分钟，搅拌溶解完全，结束。
实施例7：本发明祛痘平衡精华的制备方法：
实施例3的祛痘中药组合物60g；
按照下述步骤制备本发明祛痘平衡精华：
(1)称取30g甘油、20g烟酰胺、0.1g丙烯酸(酯)类/C10-30烷醇丙烯酸酯交联聚合物混合均匀，得到A相料；
(2)将753g水、A相料、20g丙二醇、3g黄原胶、2g羟乙基纤维素，0.1g对羟基苯乙酮、0.3g 1,2戊二醇依次加入水锅中，加热到80-85℃，搅拌至溶解均匀，保温20min；
(3)开冷却循环水、搅拌降温，得温度降至45-50℃时，将0.8g精氨酸、0.8g己脒定二(羟乙基磺酸)盐、56g水杨酸羟丙基倍他环糊精包合物、2g苯氧乙醇、0.7g氯苯甘醚依次加入反应罐中，均质1分钟，搅拌溶解完全；
(4)继续搅拌冷却至低于37℃，将0.01g季铵盐-73、实施例3的60g祛痘中药组合物、30g库拉索芦荟提取物、1g葡糖酸锌和20g无水乙醇,依次加入反应罐中，均质2-3分钟，搅拌溶解完全，结束。
实施例8：本发明祛痘平衡精华的制备方法：
实施例4的祛痘中药组合物150g；
按照下述步骤制备本发明祛痘平衡精华：
(1)称取70g甘油、100g烟酰胺、30g丙烯酸(酯)类/C10-30烷醇丙烯酸酯交联聚合物混合均匀，得到A相料；
(2)将313g水、A相料、100g丙二醇、10g黄原胶、4g羟乙基纤维素，0.6g对羟基苯乙酮、1g 1,2戊二醇依次加入水锅中，加热到80-85℃，搅拌至溶解均匀，保温20min；
(3)开冷却循环水、搅拌降温，得温度降至45-50℃时，将1.9g精氨酸、1.0g己脒定二(羟乙基磺酸)盐、80g水杨酸羟丙基倍他环糊精包合物、10g苯氧乙醇、2g氯苯甘醚依次加入反应罐中，均质1分钟，搅拌溶解完全；
(4)继续搅拌冷却至低于37℃，将0.04g季铵盐-73、实施例4的150g祛痘中药组合物、70g库拉索芦荟提取物、7g葡糖酸锌和50g无水乙醇,依次加入反应罐中，均质2-3分钟，搅拌溶解完全，结束。
试验例一：细菌抑菌功效评价
供试菌种：金黄色葡萄球菌、痤疮丙酸杆菌
培养基与培养条件：营养琼脂培养基(36±1℃温箱培养48±2h，用于金黄色葡萄球菌)、疱肉培养基(36±1℃培养24-72小时，用于痤疮丙酸杆菌培养)。
实施例1-4，对比例1-2均取60g用质量分数20％的丙二醇溶解至1000ml用于检测.
空白为质量分数20％的丙二醇。
表1：各实施例、对比例、空白样品纸片扩散法(K-B法)对细菌的抑菌圈直径(
n＝6)
由表1数据可知本发明的中药组合物君药苦参碱，与臣药：蛇床子提取物、黄芩提取物、忍冬花提取物、蒲公英提取物、黄柏提取物和蔓生百部提取物复配对痤疮的致病细菌具有明显的协同抑制作用，抑菌圈明显。
试验例二：控油功效评价
通过测量吸油胶带吸收皮脂后的透明度，测得皮肤表面皮脂量。
1.试剂和材料
1.1无屑吸水干纸巾；1.2碱性皂基清洁产品：其10％(w/w)水溶液pH值范围在10-11内；1.3乳胶指套；1.4注射器。
2.仪器
2.1皮肤表面皮脂测试仪Sebumeter。
2.2分析天平；精度0.0001g。
3.试验条件和受试者要求
3.1测试条件
3.1.1测试环境温度：20℃-22℃，相对湿度：40％-60％，并且进行实时动态监测。
3.1.2测试过程中的测试条件应保持一致，如：测试者，场所，仪器等。
3.2受试者要求
3.2.1受试者人数：有效例数30例以上。
3.2.2受试者要求
3.2.2.118岁-45岁符合试验要求的志愿者：
受试者纳入标准：按自愿原则选择18-45岁身体健康，经问诊合格均可进行试用观察。
受试者排除标准：(1)过敏者，(2)合并有心肝肾和造血系统等严重原发性疾病、精神病患者，(3)不符合纳入标准，未按规定使用受试物，无法判定功效或资料不全影响功效判断者。
3.2.2.2在测试人员管理下，志愿者用碱性皂基清洁产品清洁面部，清水冲洗干净后用无屑水干纸巾吸干，在符合标准的测试环境中静坐，前额暴露，保持放松，避免触碰前额及两颊。使用皮肤表面皮脂测试仪Sebumeter测量前额的皮肤表面皮脂量，志愿者前额皮脂量在8h内超过120μg/cm2者作为受试者。
4.测试步骤
4.1测试前的准备
受试部位为前额，样品涂抹区域和对照区域随机分布在前额左、右侧，样品涂抹区域和对照区域面积一致，各区域面积至少3cm×3cm，区域间隔至少1cm，确保样品涂抹区域在统计学上达到平衡。
测试前，受试者在符合标准的测试环境中静坐至少20min，不能喝水和饮料，受试者前额暴露，保持放松，避免触碰受试部位。
4.2测定：
按照皮肤表面皮脂测试仪使用说明进行测试。
在测试人员管理下，受试者用碱性皂基清洁产品清洁受试部位，清水冲洗干净后用无屑吸水干纸巾吸干。3min内，分别测量样品涂抹区域和对照区域皮肤表面皮脂量，在各区域内不同位置测量3次，测量结果以3次测量平均值表示，作为初始值，
样品按(2.0±0.1)mg/cm2的用量进行单次涂抹，通过注射器进行定量取样，使用乳胶指套将样品均匀涂抹于规定区域内，并记录实际涂样量。
在设定的测量时间点，分别在样品涂抹区域和对照区域内不同位置测量3次，获得各区域皮肤表面皮脂量，测量结果以每次扣除空白值之后3次测量的平均值表示。
受试者每日早、晚各一次，分别于洁面后涂抹。涂抹10天后测试。测试期间，受试者前额暴露，避免触碰受试部位。同一个受试者的测试必须使用同一仪器由同一测试人员完成。
测试样品：实施例5-8，对照为空白。
表2本发明祛痘平衡精华涂抹前后，皮肤油分参数测定(n＝35)
注：使用前后比较P<0.05。
由表2数据可知，本发明祛痘平衡精华皮肤控油效果明显，以实施例5的祛痘平衡精华控油效果最佳。
试验例三、刺激性测试
将本发明实施例5-8制备的祛痘平衡精华送往第三方检测机构检测皮肤刺激性，对每个精华液均用6鸡胚连续皮肤刺激性实验，且试验组的鸡胚的出血、凝血和血管融解时间均高于300分钟。
结果显示，上述实施例制备的祛痘平衡精华计算得到的刺激评分均为零分，说明本发明实施例5-8制备的祛痘平衡精华为无刺激性产品。
试验例四：本发明祛痘平衡精华人体评价
按照“卫生部皮肤病药物临床研究指导原则”来进行分级判定(GB15797-2002“一次性使用卫生用品卫生标准”)
1.痊愈：皮损消退；2.显效：皮损消退>60％；红斑的肿痛消失，粉刺消退；
3.有效：皮损消退>20-60％；红斑的痛感减轻，粉刺部分消退或消失；
4.无效：皮损消退<20％或加重；红斑的肿痛仍在，粉刺无改善。
从试用者自我评估的结果可以看出，本发明实施例所提供的祛痘平衡精华对多数试用者肌肤具有较好的改善肌肤炎症反应、祛痘的效果，实现了抑菌消炎祛痘的目的。
试验例五、稳定性测试
测试样品：
实验组为取实施例5-8制备的祛痘平衡精华。
空白组为各取实施例5-8制备的祛痘平衡精华常温保存。
1、耐热测试
该耐热试验是将各处于室温的测试样品直接放入40±1℃的烘箱保持24h，恢复至室温后，观察测试样品是否与试验前无明显差异。结果见表2所示。
2、耐寒测试
该耐寒试验是将各处于室温的测试样品直接放入-10℃的低温箱保持24h，恢复至室温后，观察测试样品是否与试验前无明显差异。结果见表2所示。
表2稳定性测试结果
结果表明，本发明实施例5-8制备的祛痘平衡精华在耐热测试及耐寒测试恢复至室温后均与空白组相比无异常情况，说明含有本发明的精华液稳定性良好，可以长期储藏。
上述实施例仅例示性说明本发明的原理及其功效，而非用于限制本发明。任何熟悉此技术的人士皆可在不违背本发明的精神及范畴下，对上述实施例进行修饰或改变。因此，举凡所属技术领域中具有通常知识者在未脱离本发明所揭示的精神与技术思想下所完成的一切等效修饰或改变，仍应由本发明的权利要求所涵盖。
Claims (6)
1.一种祛痘中药组合物，其特征在于，所述组合物包括：苦参碱20-40份、蛇床子提取物24-30份、黄芩提取物20-28份、忍冬花提取物17-24份、蒲公英提取物12-20份、黄柏提取物11-17份和蔓生百部提取物9-14份。
2.按照权利要求1所述的祛痘中药组合物，其特征在于，所述组合物由如下重量份的组分组成：苦参碱30份、蛇床子提取物28份、黄芩提取物24份、忍冬花提取物20份、蒲公英提取物16份、黄柏提取物14份和蔓生百部提取物11份。
3.按照权利要求1或2所述的祛痘中药组合物在制备祛痘护肤品中的应用。
4.一种祛痘平衡精华，其特征在于，所述祛痘平衡精华包括如下重量百分比计的原料：
权利要求1或2所述的祛痘中药组合物6-34％；
增效祛痘成分：葡糖酸锌0.1-0.7％、季铵盐-73 0.001-0.004％、水杨酸羟丙基倍他环糊精包合物5.6-8％和己脒定二(羟乙基磺酸)盐0.08-0.10％；
辅助营养修复成分：精氨酸0.08-0.19％、烟酰胺3-10％和库拉索芦荟提取物3-7％；
增稠稳定剂：丙烯酸(酯)类/C10-30烷醇丙烯酸酯交联聚合物0.01-3％、黄原胶0.3％-1％和羟乙基纤维素0.2-0.4％；
抗菌成分：苯氧乙醇0.2％-1％、氯苯甘醚0.07-0.2％、1,2戊二醇0.03-0.1％和对羟基苯乙酮0.01-0.06％；
甘油3-7％、丙二醇2～l0％和乙醇2-5％；
其余重量为去离子水。
5.按照权利要求4所述的祛痘平衡精华，其特征在于，包括如下重量百分比计的原料：
权利要求1或2所述的祛痘中药组合物25％；
增效祛痘成分：葡糖酸锌0.3％、季铵盐-730.002％、水杨酸羟丙基倍他环糊精包合物7％和己脒定二(羟乙基磺酸)盐0.09％；
辅助营养修复成分：精氨酸0.15％、烟酰胺2.4％和库拉索芦荟提取物7％；
增稠稳定剂：丙烯酸(酯)类/C10-30烷醇丙烯酸酯交联聚合物2％、黄原胶0.6％和羟乙基纤维素0.3％；
抗菌剂：苯氧乙醇0.2％、氯苯甘醚0.1％、1,2戊二醇0.05％和对羟基苯乙酮0.03％、甘油3.5％、丙二醇0.2％、乙醇2％；
其余重量为去离子水。
6.按照权利要求4或5所述祛痘平衡精华的制备方法，其特征在于，所述制备方法包括步骤：
(1)将所述重量百分比的甘油、丁二醇、烟酰胺、丙烯酸(酯)类/C10-30烷醇丙烯酸酯交联聚合物混合均匀，得到A相料；
(2)将所述重量百分比的水、A相料、丙二醇、黄原胶、羟乙基纤维素，对羟基苯乙酮、1,2戊二醇依次加入水锅中，加热到80-85℃，搅拌至溶解均匀，保温20min；
(3)开冷却循环水、搅拌降温，得温度降至45-50℃时，将所述重量百分比的精氨酸、己脒定二(羟乙基磺酸)盐、水杨酸羟丙基倍他环糊精包合物、苯氧乙醇、氯苯甘醚依次加入反应罐中，均质1分钟，搅拌溶解完全；
(4)继续搅拌冷却至低于37℃，将所述重量百分比的季铵盐-73、植物提取物、葡糖酸锌乙醇，依次加入反应罐中，均质2-3分钟，搅拌溶解完全，结束。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010479732.9A CN111588815B (zh) | 2020-05-29 | 2020-05-29 | 一种外用祛痘中药组合物及其应用与含有该组合物的祛痘平衡精华 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010479732.9A CN111588815B (zh) | 2020-05-29 | 2020-05-29 | 一种外用祛痘中药组合物及其应用与含有该组合物的祛痘平衡精华 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111588815A true CN111588815A (zh) | 2020-08-28 |
| CN111588815B CN111588815B (zh) | 2021-12-14 |
Family
ID=72179458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010479732.9A Expired - Fee Related CN111588815B (zh) | 2020-05-29 | 2020-05-29 | 一种外用祛痘中药组合物及其应用与含有该组合物的祛痘平衡精华 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111588815B (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112294887A (zh) * | 2020-12-05 | 2021-02-02 | 赣州佰珍堂生物科技有限公司 | 一种具有祛痘除疤功能的中药制备工艺 |
| CN113456534A (zh) * | 2021-07-29 | 2021-10-01 | 国药医养化妆品研发(杭州)有限公司 | 一种具有多重护肤功效的控油祛痘混合物及其制备方法 |
| CN114392225A (zh) * | 2022-01-27 | 2022-04-26 | 广州兰皙化妆品有限公司 | 一种祛痘精华液及其制备方法 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105342889A (zh) * | 2015-11-26 | 2016-02-24 | 珠海蕾特恩国际贸易有限公司 | 祛痘霜及其制备方法 |
| CN105362143A (zh) * | 2015-11-26 | 2016-03-02 | 珠海蕾特恩国际贸易有限公司 | 祛痘菁华及其制备方法 |
| CN106727051A (zh) * | 2017-02-28 | 2017-05-31 | 高宝化妆品（中国）有限公司 | 一种中药祛痘精华及其制备方法 |
| CN109157450A (zh) * | 2018-10-16 | 2019-01-08 | 广州科玛生物科技股份有限公司 | 一种祛痘精华乳 |
| CN110368348A (zh) * | 2019-08-29 | 2019-10-25 | 广州重生化妆品实业有限公司 | 一种祛痘原液的配方及其制备方法 |
-
2020
- 2020-05-29 CN CN202010479732.9A patent/CN111588815B/zh not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105342889A (zh) * | 2015-11-26 | 2016-02-24 | 珠海蕾特恩国际贸易有限公司 | 祛痘霜及其制备方法 |
| CN105362143A (zh) * | 2015-11-26 | 2016-03-02 | 珠海蕾特恩国际贸易有限公司 | 祛痘菁华及其制备方法 |
| CN106727051A (zh) * | 2017-02-28 | 2017-05-31 | 高宝化妆品（中国）有限公司 | 一种中药祛痘精华及其制备方法 |
| CN109157450A (zh) * | 2018-10-16 | 2019-01-08 | 广州科玛生物科技股份有限公司 | 一种祛痘精华乳 |
| CN110368348A (zh) * | 2019-08-29 | 2019-10-25 | 广州重生化妆品实业有限公司 | 一种祛痘原液的配方及其制备方法 |
Non-Patent Citations (1)
| Title |
|---|
| 汪晓艳: "自拟祛痘方内服外洗治疗青少年青春痘42例", 《中医药临床杂志》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112294887A (zh) * | 2020-12-05 | 2021-02-02 | 赣州佰珍堂生物科技有限公司 | 一种具有祛痘除疤功能的中药制备工艺 |
| CN113456534A (zh) * | 2021-07-29 | 2021-10-01 | 国药医养化妆品研发(杭州)有限公司 | 一种具有多重护肤功效的控油祛痘混合物及其制备方法 |
| CN114392225A (zh) * | 2022-01-27 | 2022-04-26 | 广州兰皙化妆品有限公司 | 一种祛痘精华液及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111588815B (zh) | 2021-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111588815B (zh) | 一种外用祛痘中药组合物及其应用与含有该组合物的祛痘平衡精华 | |
| CN111494282B (zh) | 一种退红抗炎控油祛痘组合物及其应用与含有该组合物的祛痘平衡精华乳 | |
| CN102283792B (zh) | 一种天然祛痘乳霜 | |
| CN105395467B (zh) | 一种中药组合物、美肤化妆品及其应用 | |
| CN109157451B (zh) | 一种祛痘洁面乳 | |
| KR20100016450A (ko) | 피부 외용제 조성물 | |
| CN103202892B (zh) | 具有祛痘功效的中药组合物、护肤精华素及其制备方法 | |
| CN105411960A (zh) | 一种具有抑制痤疮功效的面膜及其制备方法 | |
| CN111743830A (zh) | 一种祛痘组合物及其应用 | |
| CN108143639A (zh) | 一种祛痘霜及其制备方法 | |
| CN109260059B (zh) | 一种具有祛痘和皮肤修复功效的精油组合物及应用 | |
| CN102139033A (zh) | 一种治疗孕妇剖腹产术后皮肤创伤的中药组合物 | |
| CN111419756A (zh) | 一种去屑止痒护理精华及其生产工艺 | |
| CN105251011B (zh) | 一种用于浅度烧伤的喷膜剂及其制备方法 | |
| CN112451447A (zh) | 一种温和不刺激的高效祛痘组合物及其制备方法 | |
| CN106726998A (zh) | 一种含茶树花提取液的祛痘液 | |
| CN112516066B (zh) | 一种控油组合物及其在化妆品中的应用 | |
| KR102249700B1 (ko) | 박하초를 함유하는 화장료 조성물 | |
| CN117338691A (zh) | 控油组合物及其制备方法 | |
| CN103230359B (zh) | 具有祛痘功效的护肤组合物、面膜及其制备方法 | |
| CN115054566B (zh) | 一种抗头皮衰老组合物及其制备方法 | |
| CN115337233B (zh) | 一种具有温和祛痘功效的凝胶面膜及其制备方法 | |
| CN109364290A (zh) | 一种薰衣草精油脂质体液体创可贴及其制备方法 | |
| CN115414308A (zh) | 一种祛痘组合物及制备方法和应用 | |
| CN108852944A (zh) | 一种以opc为载体的十三肽抗菌修复乳液及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20211214 |